Innovus Pharmaceuticals Inc (NASDAQ:INNV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “

Shares of Innovus Pharmaceuticals (NASDAQ:INNV) traded down 6.4685% during midday trading on Monday, hitting $0.2675. 538,025 shares of the stock traded hands. The company’s market cap is $23.32 million. Innovus Pharmaceuticals has a 52-week low of $0.03 and a 52-week high of $0.66. The stock has a 50-day moving average of $0.29 and a 200-day moving average of $0.26.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Innovus Pharmaceuticals Company Profile

Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.

5 Day Chart for NASDAQ:INNV

Get a free copy of the Zacks research report on Innovus Pharmaceuticals (INNV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Innovus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals Inc and related companies with's FREE daily email newsletter.